0001127602-23-010081.txt : 20230314
0001127602-23-010081.hdr.sgml : 20230314
20230314161824
ACCESSION NUMBER: 0001127602-23-010081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230313
FILED AS OF DATE: 20230314
DATE AS OF CHANGE: 20230314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Alpuche Charles
CENTRAL INDEX KEY: 0001665678
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33462
FILM NUMBER: 23731245
MAIL ADDRESS:
STREET 1: C/O INSULET CORPORATION
STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200
CITY: BILLERICA
STATE: MA
ZIP: 01821
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INSULET CORP
CENTRAL INDEX KEY: 0001145197
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 043523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 NAGOG PARK
CITY: ACTON
STATE: MA
ZIP: 01720
BUSINESS PHONE: 978-600-7000
MAIL ADDRESS:
STREET 1: 100 NAGOG PARK
CITY: ACTON
STATE: MA
ZIP: 01720
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2023-03-13
0001145197
INSULET CORP
PODD
0001665678
Alpuche Charles
C/O INSULET CORPORATION
100 NAGOG PARK
ACTON
MA
01720
1
Advisor
Common Stock
2023-03-13
4
M
0
23401
31.21
A
68985
D
Common Stock
2023-03-13
4
S
0
23401
305.15
D
45584
D
Employee Stock Option (Right to Buy)
31.21
2023-03-13
4
M
0
23401
0
D
2026-02-03
Common Stock
23401
12347
D
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $302.98 to $307.17. Specifically: 8,975 shares were sold in the range of $302.98 to $303.98, with a weighted average share price of $303.60; 1,100 shares were sold in the range of $304.01 to $304.29, with a weighted average share price of $304.08; 7,524 shares were sold in the range of $305.35 to $306.35, with a weighted average share price of $305.94;
Footnote continued: and 5802 shares were sold in the range of $306.41 to $307.17, with a weighted average share price of $306.74. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.
/s/ Patricia K. Dolan, attorney-in-fact
2023-03-14